Swiss HIV Cohort Study
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
Zinkernagel A, Weber R, Schmid P, Bernasconi E, Opravil M, Tarr P, Hirschel B, Battegay M, Furrer H, Rickenbach M, Ledergerber B, von Wyl V, Swiss HIV Cohort Study. Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study. Antiviral therapy 2006; 11:131-42.
01.01.2006Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study
01.01.2006Antiviral therapy 2006; 11:131-42
Zinkernagel Annelies S, Weber Rainer, Schmid Patrick, Bernasconi Enos, Opravil Milos, Tarr Philip E, Hirschel Bernard, Battegay Manuel, Furrer Hansjakob, Rickenbach Martin, Ledergerber Bruno, von Wyl Viktor, Swiss HIV Cohort Study
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
Karrer U, Speck R, Weber R, Russotti M, Schmid P, Hirschel B, Gayet-Ageron A, Cavassini M, Battegay M, Elzi L, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS (London, England) 2005; 19:1987-94.
18.11.2005Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
18.11.2005AIDS (London, England) 2005; 19:1987-94
Karrer Urs, Speck Roberto F, Weber Rainer, Russotti Marina, Schmid Patrick, Hirschel Bernard, Gayet-Ageron Angèle, Cavassini Matthias, Battegay Manuel, Elzi Luigia, Furrer Hansjakob, Ledergerber Bruno, Swiss HIV Cohort Study
Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy
Wunder D, Furrer H, Schmid P, Schiffer V, Bucher H, Cavassini M, Bernasconi E, Weber R, Fux C, Bersinger N, Swiss HIV Cohort Study. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS (London, England) 2005; 19:1837-42.
04.11.2005Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy
04.11.2005AIDS (London, England) 2005; 19:1837-42
Wunder Dorothea, Furrer Hansjakob, Schmid Patrick, Schiffer Véronique, Bucher Heiner C, Cavassini Matthias, Bernasconi Enos, Weber Rainer, Fux Christoph, Bersinger Nick A, Swiss HIV Cohort Study
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6.
01.11.2005HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss
01.11.2005Journal of acquired immune deficiency syndromes (1999) 2005; 40:250-6
Schüpbach Jörg, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Furrer Hansjakob, Battegay Manuel, Perrin Luc, Yerly Sabine, Tomasik Zuzana, Böni Jürg, Fischer Marek, Joos Beda, Günthard Huldrych, Swiss HIV Cohort Study
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
Rotger M, Telenti A, Rickenbach M, Bernasconi E, Drechsler H, Vernazza P, Furrer H, Günthard H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. The Journal of infectious diseases 2005; 192:1381-6.
15.10.2005Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia
15.10.2005The Journal of infectious diseases 2005; 192:1381-6
Rotger Margalida, Telenti Amalio, Rickenbach Martin, Bernasconi Enos, Drechsler Henning, Vernazza Pietro, Furrer Hansjakob, Günthard Huldrych F, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Cavassini M, Vernazza P, Opravil M, Perrin L, Ledergerber B, Furrer H, Swiss HIV Cohort Study. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72.
01.08.2005Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy
01.08.2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:361-72
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Cavassini Matthias, Vernazza Pietro, Opravil Milos, Perrin Luc, Ledergerber Bruno, Furrer Hansjakob, Swiss HIV Cohort Study
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
Rauch A, Furrer H, Evison J, Zinkernagel A, Bernasconi E, Vernazza P, Bucher H, Tarr P, Hirschel B, Weber R, Rickenbach M, Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:395-402.
01.08.2005Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
01.08.2005Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005; 41:395-402
Rauch Andri, Furrer Hansjakob, Evison John, Zinkernagel Annelies S, Bernasconi Enos, Vernazza Pietro, Bucher Heiner C, Tarr Philip E, Hirschel Bernard, Weber Rainer, Rickenbach Martin, Swiss HIV Cohort Study
Starting or changing therapy - a prospective study exploring antiretroviral decision-making
Fehr J, Battegay M, Spirig R, Jäger H, Vernazza P, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study. Starting or changing therapy - a prospective study exploring antiretroviral decision-making. Infection 2005; 33:249-56.
01.08.2005Starting or changing therapy - a prospective study exploring antiretroviral decision-making
01.08.2005Infection 2005; 33:249-56
Fehr J S, Battegay M, Spirig R, Jäger H, Vernazza Pietro, Bregenzer T, Kiss A, Wagels T, Wolf E, Sendi P, Nicca D, Swiss HIV Cohort Study
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
Tarr P, Telenti A, Ledergerber B, Rickenbach M, Darioli R, Bernasconi E, Vernazza P, Weber R, Battegay M, Hirschel B, Martinez R, Rotger M, Furrer H, Bleiber G, Taffé P, Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. The Journal of infectious diseases 2005; 191:1419-26.
01.05.2005Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders
01.05.2005The Journal of infectious diseases 2005; 191:1419-26
Tarr Philip E, Telenti Amalio, Ledergerber Bruno, Rickenbach Martin, Darioli Roger, Bernasconi Enos, Vernazza Pietro, Weber Rainer, Battegay Manuel, Hirschel Bernard, Martinez Raquel, Rotger Margalida, Furrer Hansjakob, Bleiber Gabriela, Taffé Patrick, Swiss HIV Cohort Study
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
Opravil M, Perrin L, Ledergerber B, Vernazza P, Blasko M, Bernasconi E, Calmy A, Furrer H, Chave J, Baumann D, Swiss HIV Cohort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS (London, England) 2004; 18:2213-5.
05.11.2004Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine
05.11.2004AIDS (London, England) 2004; 18:2213-5
Opravil Milos, Perrin Luc, Ledergerber Bruno, Vernazza Pietro, Blasko Monika, Bernasconi Enos, Calmy Alexandra, Furrer Hansjakob, Chave Jean-Philippe, Baumann Doris, Swiss HIV Cohort Study
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
Trkola A, Günthard H, Bonhoeffer S, Hirschel B, Weber R, Bernasconi E, Vernazza P, Battegay M, Furrer H, Fagard C, Oxenius A, Leemann C, Kuster H, Swiss HIV Cohort Study. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 2004; 104:1784-92.
15.09.2004Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point
15.09.2004Blood 2004; 104:1784-92
Trkola Alexandra, Günthard Huldrych F, Bonhoeffer Sebastian, Hirschel Bernard, Weber Rainer, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Furrer Hansjakob, Fagard Catherine, Oxenius Annette, Leemann Christine, Kuster Herbert, Swiss HIV Cohort Study
Is unsafe sexual behaviour increasing among HIV-infected individuals?
Glass T, Bucher H, Battegay M, Hirschel B, Cavassini M, Weber R, Rickenbach M, Vernazza P, Young J, Swiss HIV Cohort Study. Is unsafe sexual behaviour increasing among HIV-infected individuals?. AIDS (London, England) 2004; 18:1707-14.
20.08.2004Is unsafe sexual behaviour increasing among HIV-infected individuals?
20.08.2004AIDS (London, England) 2004; 18:1707-14
Glass Tracy R, Bucher Heiner C, Battegay Manuel, Hirschel Bernard, Cavassini Matthias, Weber Rainer, Rickenbach Martin, Vernazza Pietro, Young Jim, Swiss HIV Cohort Study
Infrequent transmission of HIV-1 drug-resistant variants
Yerly S, Perrin L, Hirschel B, Perneger T, Bernard M, Gebhardt M, Rickenbach M, Bürgisser P, Chanzy B, Furrer H, Battegay M, Vernazza P, Chave J, Kaiser L, Flepp M, Telenti A, Jost S, Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. Antiviral therapy 2004; 9:375-84.
01.06.2004Infrequent transmission of HIV-1 drug-resistant variants
01.06.2004Antiviral therapy 2004; 9:375-84
Yerly Sabine, Perrin Luc, Hirschel Bernard, Perneger Thomas, Bernard Marie-Charlotte, Gebhardt Martin, Rickenbach Martin, Bürgisser Philippe, Chanzy Bruno, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Chave Jean-Philippe, Kaiser Laurent, Flepp Markus, Telenti Amalio, Jost Stéphanie, Swiss HIV Cohort Study
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
Kaufmann G, Battegay M, Hirschel B, Rickenbach M, Bernasconi E, Vernazza P, Ledergerber B, Cavassini M, Furrer H, Perrin L, Weber R, Khanna N, Swiss HIV Cohort Study. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antiviral therapy 2004; 9:263-74.
01.04.2004Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection
01.04.2004Antiviral therapy 2004; 9:263-74
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Rickenbach Martin, Bernasconi Enos, Vernazza Pietro, Ledergerber Bruno, Cavassini Matthias, Furrer Hansjakob, Perrin Luc, Weber Rainer, Khanna Nina, Swiss HIV Cohort Study
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial
Ananworanich J, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S, Cavassini M, Bernasconi E, Nüesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Swiss HIV Cohort Study. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS (London, England) 2003; 17:F33-7.
17.10.2003Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial
17.10.2003AIDS (London, England) 2003; 17:F33-7
Ananworanich Jintanat, Ebnöther C, Fagard C, Genné D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza Pietro, Yerly S, Cavassini M, Bernasconi E, Nüesch Reto, Le Braz Michelle, Chetchotisakd Ploechan, Vibhagool Asda, Wicharuk Saijai, Ruxrungtham Kiat, Furrer Hansjakob, Cooper David, Hirschel Bernard, Swiss HIV Cohort Study
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
Jaggy C, Hirschel B, Bernasconi E, Vernazza P, Flepp M, Battegay M, Telenti A, Furrer H, Rickenbach M, Egger M, Schwarz C, Ledergerber B, von Overbeck J, Swiss HIV Cohort Study. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362:877-8.
13.09.2003Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
13.09.2003Lancet 2003; 362:877-8
Jaggy Christian, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Flepp Markus, Battegay Manuel, Telenti Amalio, Furrer Hans-Jakob, Rickenbach Martin, Egger Matthias, Schwarz Claude, Ledergerber Bruno, von Overbeck Jan, Swiss HIV Cohort Study
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study
Wolf K, Bucher H, Weber R, Telenti A, Hirschel B, Bernasconi E, Furrer H, Flepp M, Vernazza P, Rickenbach M, Young J, Swiss HIV Cohort Study. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2003; 33:494-9.
01.08.2003Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study
01.08.2003Journal of acquired immune deficiency syndromes (1999) 2003; 33:494-9
Wolf Katja, Bucher Heiner C, Weber Rainer, Telenti Amalio, Hirschel Bernard, Bernasconi Enos, Furrer Hansjakob, Flepp Markus, Vernazza Pietro, Rickenbach Martin, Young James, Swiss HIV Cohort Study
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
Fagard C, Hirschel B, Perrin L, Perneger T, Oxenius A, Ebnöther C, Telenti A, Bernasconi E, Vernazza P, Egger M, Hirsch H, Günthard H, Le Braz M, Swiss HIV Cohort Study. A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. AIDS (London, England) 2003; 17:1487-92.
04.07.2003A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
04.07.2003AIDS (London, England) 2003; 17:1487-92
Fagard Catherine, Hirschel Bernard, Perrin Luc, Perneger Thomas, Oxenius Annette, Ebnöther Corinna, Telenti Amalio, Bernasconi Enos, Vernazza Pietro, Egger Martin, Hirsch Hans H, Günthard Huldrych, Le Braz Michelle, Swiss HIV Cohort Study
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
Fagard C, Price D, Dawson S, Klimkait T, Perneger T, McLean A, Clotet B, Gatell J, Perrin L, Plana M, Phillips R, Hirschel B, Yerly S, Leduc D, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Archives of internal medicine 2003; 163:1220-6.
26.05.2003A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
26.05.2003Archives of internal medicine 2003; 163:1220-6
Fagard Catherine, Price David, Dawson Sara J, Klimkait Thomas, Perneger Thomas V, McLean Angela, Clotet Bonaventura, Gatell Jose M, Perrin Luc, Plana Montserrat, Phillips Rodney, Hirschel Bernard, Yerly Sabine, Leduc Dominique, Oxenius Annette, Günthard Huldrych, Garcia Felipe, Le Braz Michelle, Mestre Gabriel, Battegay Manuel, Furrer Hansjakob, Vernazza Pietro, Bernasconi Enos, Telenti Amalio, Weber Rainer, Swiss HIV Cohort Study
Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
Bucher H, Battegay M, Minder C, Vernazza P, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. HIV medicine 2002; 3:247-53.
01.10.2002Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study
01.10.2002HIV medicine 2002; 3:247-53
Bucher H C, Battegay M, Minder C, Vernazza Pietro, Bernasconi E, Weber R, Hirschel B, Telenti A, Furrer H, Taffé P, Bichsel M, Swiss HIV Cohort Study